MedTrace Logo

Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation

NCT00930241 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-08-22

No results posted yet for this study

Summary

This study is a prospective randomized trial to compare twice daily to once daily administration of the basic immunosuppressive regimen in lung transplanted patients.

Conditions

  • Lung Transplantation

Interventions

DRUG

Advagraf®

Advagraf® (one daily dose of Tacrolimus)

DRUG

Prograf®

Prograf® (two daily doses of Tacrolimus)

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Jens T Gottlieb, M.D. · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930241 on ClinicalTrials.gov